How Can Molecular Diagnostic Companies Show Value if Insurers Won't Pay?
FOR IMMEDIATE RELEASE FEBRUARY 20, 2014
Prostate Cancer Test Shows Role of ‘Clinical Utility’
How Can Molecular Diagnostic Companies Show Value if Insurers Won’t Pay?
PLAINSBORO, N.J. — A test that could determine whether a man with signs of prostate cancer needs a second biopsy seems a no-brainer, correct? Not unless the insurer paying for it is convinced that his doctor’s decision will turn on the outcome of that test.
Welcome to the world of clinical utility, the new bar that molecular diagnostic testing companies must meet as insurance companies, Medicare and Medicaid strive to hold down costs, just as the possibilities of personalized medicine seem boundless. A story in the current issue of Evidence-Based Oncology, a news publication of The American Journal of Managed Care, explores how the demand for proof of clinical utility has affected the marketing of MDxHealth’s promising new epigenetic test for prostate cancer, called Confirm MDx. Peer-reviewed research pegs the test’s savings at $500,000 a year for a commercial plan of 1 million members.
The standard of clinical utility, versus the old standard of clinical validity — which meant the test was accurate – came into vogue around 2011, after the concept appeared in the literature and a white paper by United Healthcare estimated that the payer spent 14 percent more on genetic and diagnostic testing per patient in 2010 than it did in 2008.
Payers’ concerns about molecular diagnostics stem from fears that for all their promise, such tests do not always change the ways doctors practice medicine. Payers want to know that the tests are actually preventing extra costly procedures, not just providing additional information. Thus, payers are demanding evidence of that the tests are changing physician behavior. But testing companies say such proof is hard to come by if insurers won’t pay for the tests in the first place, because a lack of reimbursement can essentially deny access for many patients.
For the full story, click here.
CONTACT: Mary Caffrey (609) 716-7777 x 144
www.ajmc.com Follow us on @EBOncology
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Imetelstat Offers Benefits for Patients With MDS Who Are Red Blood Cell–Transfusion Dependent
December 5th 2023The past year has offered new hope for patients with lower-risk myelodysplastic syndromes. Besides imetelstat, which has an FDA deadline for action of June 2024, the agency approved luspatercept, which has a different mechanism of action.
Read More
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
Hospitals Report Declining Cash Reserves, Increasing Reimbursement Delays and Denials
December 1st 2023A new report highlighting the twin pressures hospitals have faced over the last 18 months shows that as reimbursement delays and denials increased and cash and investments decreased, operating expenses have risen sharply.
Read More